Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-25-032468
Filing Date
2025-04-16
Accepted
2025-04-16 13:42:48
Documents
15
Period of Report
2025-04-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0238544-8ka1_abvcbio.htm   iXBRL 8-K/A 33501
2 PRESS RELEASE ea023854401ex99-1_abvc.htm EX-99.1 18898
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2254
  Complete submission text file 0001213900-25-032468.txt   237879

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE abvc-20250415.xsd EX-101.SCH 3020
5 XBRL LABEL FILE abvc-20250415_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE abvc-20250415_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0238544-8ka1_abvcbio_htm.xml XML 4177
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40700 | Film No.: 25842052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)